Genta Inc. (GETA.OB) Shares Soar on FDA Fast Track Designation for Gastric Cancer Candidate
Biopharmaceutical company Genta Inc. focuses on innovative products for cancer treatment. The U.S. Food and Drug Administration (FDA) has granted Genta’s request for Fast Track designation of the company’s late phase 2 oncology product tesetaxel for treatment of patients with advanced gastric cancer. The FDA grants Fast Track designation in order to accelerate the review of new drugs that are intended to treat serious or life-threatening conditions. The designation typically opens the door for the company to submit New Drug Application (NDA) on a "rolling" basis with ongoing FDA review during the submission process. In the completed phase 2a study,…